In short
A groundbreaking clinical trial is underway to evaluate the safety and effectiveness of CLDN6 CAR-T(A), an innovative cell therapy, in patients with advanced solid tumors. This Phase I/IIa study aims to assess the potential of this treatment, both alone and in combination with a specialized RNA-based vaccine, offering hope for patients with limited treatment options.
At a glance
- Study Type
- Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts
- Treatment
- CLDN6 CAR-T(A) with or without CLDN6 RNA-LPX vaccine
- Target Population
- Patients with CLDN6-positive relapsed or refractory advanced solid tumors
- Primary Objectives
- Assess safety, tolerability, and comparability of manual and automated CLDN6 CAR-T processes
- Secondary Objectives
- Evaluate immune factor profiles and anti-tumor activity
- Key Eligibility Criteria
- CLDN6-positive tumor, adequate organ function, measurable disease, age ≥18 years
- Primary Endpoints
- Treatment-emergent adverse events, dose-limiting toxicities
- Secondary Endpoints
- Changes in immune factors, objective response rate, duration of response
What is CLDN6 CAR-T(A)?
CLDN6 CAR-T(A) is an innovative investigational cell therapy being developed for the treatment of advanced solid tumors. It belongs to a class of treatments known as CAR-T cell therapies, which use a patient's own immune cells to fight cancer. The "CLDN6" in its name refers to Claudin 6, a specific protein found on some cancer cells that this therapy targets.
How does it work?
CLDN6 CAR-T(A) works by modifying a patient's own T cells (a type of immune cell) to recognize and attack cancer cells that express the CLDN6 protein. Here's a simplified explanation of the process:
- T cells are collected from the patient's blood.
- These cells are genetically modified in a laboratory using a gamma-retroviral self-inactivating vector to produce a special receptor called a CAR (Chimeric Antigen Receptor) that can recognize CLDN6.
- The modified cells are then multiplied in the lab.
- Finally, these CAR-T cells are infused back into the patient, where they can seek out and destroy cancer cells expressing CLDN6.
What conditions does it target?
CLDN6 CAR-T(A) is being investigated for the treatment of several types of advanced solid tumors, including:
- Malignant solid tumors: Various types of cancers that form solid masses
- Carcinoma of unknown primary: Cancer that has spread in the body but the original site where it started is unknown
- Testicular cancer
- Non-small cell lung cancer
The therapy is designed for patients whose cancers are metastatic (spread to other parts of the body) or unresectable (cannot be completely removed by surgery), and for whom standard treatments are no longer effective or suitable.
Current Clinical Trial
CLDN6 CAR-T(A) is currently being studied in a Phase I/IIa clinical trial. This is a first-in-human study, meaning it's the first time this specific therapy is being tested in people. The trial aims to:
- Assess the safety and tolerability of CLDN6 CAR-T(A)
- Evaluate its preliminary effectiveness in treating advanced solid tumors
- Compare CLDN6 CAR-T(A) produced by manual and automated processes
The study is also investigating the use of CLDN6 CAR-T(A) in combination with another investigational treatment called CLDN6 RNA-LPX, which is a vaccine designed to enhance the effectiveness of the CAR-T cells.
Who is eligible for the trial?
The trial has specific eligibility criteria, including:
- Patients must be 18 years or older
- Have a confirmed solid tumor that expresses the CLDN6 protein
- Have cancer that is metastatic or unresectable
- Have no available standard therapy likely to provide clinical benefit
- Have adequate organ function (bone marrow, liver, kidneys)
- Be able to attend all required trial visits
There are also several exclusion criteria, such as having received prior CAR-T therapy (except CLDN6 CAR-T) or recent live virus vaccinations.
Safety and Efficacy Evaluation
The trial will closely monitor patients for side effects, particularly looking at:
- Treatment-emergent adverse events (TEAEs), especially those that are severe or serious
- Changes in levels of immune factors in the blood
- How well tumors respond to the treatment (measured by standard criteria for solid tumors)
- How long any positive responses to the treatment last
These assessments will help determine the safety profile of CLDN6 CAR-T(A) and provide initial insights into its effectiveness against solid tumors.
How is CLDN6 CAR-T(A) administered?
CLDN6 CAR-T(A) is given as an intravenous bolus, which means it's injected directly into a vein. Before receiving the CAR-T cells, patients typically undergo a process called lymphodepletion, which helps prepare their body to receive the new cells.
It's important to note that as an investigational therapy, CLDN6 CAR-T(A) is only available through clinical trials at this time. Patients interested in this treatment should discuss their options with their oncologist to determine if they might be eligible for any ongoing studies.